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Risk Factors for Stent Thrombosis
After Implantation of Sirolimus-Eluting
Stents in Diabetic and Nondiabetic Patients
The EVASTENT Matched-Cohort Registry
Jacques Machecourt, MD, FESC,* Nicolas Danchin, MD, FESC,† Jean Marc Lablanche, MD, FESC,‡
Jean Marie Fauvel, MD, FESC,§ Jean Louis Bonnet, MD, FESC, Stephanie Marliere, MD,*
Alison Foote, PHD,¶ Jean Louis Quesada,¶ Hélène Eltchaninoff, MD, FESC,#
Gérald Vanzetto, MD, PHD,* for the EVASTENT Investigators
Grenoble, Paris, Lille, Toulouse, Marseille, and Rouen, France
Objectives We sought to assess the frequency and causes of stent thrombosis in diabetic and nondiabetic patients after
implantation of sirolimus-eluting stents.
Background Safety concerns about late stent thrombosis have been raised, particularly when drug-eluting stents are used in
less highly selected patients than in randomized trials.
Methods The EVASTENT study is a matched multicenter cohort registry of 1,731 patients undergoing revascularization
exclusively with sirolimus stents; for each diabetic patient included (stratified as single- or multiple-vessel dis-
ease), a nondiabetic patient was subsequently included. Patients were treated with aspirin  clopidogrel for at
least 3 months and were followed for 465 (range 0 to 1,062) days (1-year follow-up in 98.5%). The primary end
point was a composite of stent thrombosis (according to Academic Research Consortium definitions), cardiovas-
cular death, and nonfatal myocardial infarction (major adverse cardiac events [MACE]).
Results During follow-up, MACE occurred in 78 patients (4.5%), cardiac death in 35 (2.1%), and stent thrombosis in 45
(2.6%): 30 definite, 23 subacute, and 22 late, including 9 at 6 months. In univariate analysis, the 1-year stent
thrombosis rate was 1.8 times higher in diabetic than in nondiabetic patients (3.2% vs. 1.7%; log rank p 
0.03), with diabetic patients with multiple-vessel disease experiencing the highest rate and nondiabetic single-
vessel disease patients the lowest (4.3% vs. 0.8%; p  0.001). In multivariate analysis, in addition to the inter-
ruption of antithrombotic treatment, independent stent thrombosis predictors were previous stroke, renal failure,
lower ejection fraction, calcified lesion, length stented, and insulin-requiring diabetes.
Conclusions The risk of sirolimus stent thrombosis is higher for multiple-vessel disease diabetic patients. (J Am Coll
Cardiol 2007;50:501–8) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.051s
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Dhe large reduction in restenosis rates and in the need for
arget lesion revascularization (TLR) with drug-eluting
tents (DES) in diabetic and nondiabetic patients, com-
ared with the rate of revascularizations after implantation
f bare-metal stents (BMS), has already been demonstrated
1–4). In those studies this gain was not associated with
rom the *CHU Michallon, Grenoble, France; †Hôpital Européen Georges
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harles Nicolle, Rouen, France. Supported by a research grant from the French
ealth Ministry (DHOS F2 /DSS 1A no. 2002/477).l
Manuscript received December 1, 2006; revised manuscript received March 28,
007, accepted April 10, 2007.afety concerns such as excess stent thrombosis (ST), at least
n the early follow-up period (5). However, except for 1
mall trial (4), the trials were not designed for a direct
omparison of diabetic and nondiabetic populations, and
iabetic patients included in these trials had narrow inclu-
ion and exclusion criteria. Furthermore, ST, and particu-
arly late (1 month [late angiographic stent thrombosis
LAST)]), or very late (6 months) ST has been reported
fter implantation of DES (6–8) and may be a genuine
afety concern (9). Some recent data suggest that ST rates
re higher in real life than rates previously reported (10).
utopsy studies have shown delayed healing with poorer
ndothelialization and persistent fibrin deposition after
ES implantation (11). This might increase the risk of veryate ST (12). For diabetic patients, subgroup analysis of
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Stent Thrombosis After SES in Diabetic Patients August 7, 2007:501–8recent registries of DES use have
already suggested that diabetes
mellitus may be a risk factor for
ST (10,13), and older data after
balloon angioplasty or implanta-
tion of BMS have demonstrated
higher rates of death and ST in
diabetic than in nondiabetic pa-
tients (14,15).
The present prospective study
was especially designed to ad-
dress the issue of the safety pro-
file of the sirolimus-eluting stent
(SES) in a nonrandomized man-
ner in diabetic and nondiabetic
patients. Owing to the late oc-
currence of events in some re-
cent case reports, a long-term
follow-up (3 years) is currently
being performed.
Methods
The EVASTENT (Évaluation
coût/efficacité du stent actif au
irolimus chez les patients diabétiques et non diabétiques)
tudy is an independent matched-cohort registry, funded by
he French Health Ministry, to evaluate the safety and the
fficacy of SES in diabetic and nondiabetic patients and
ccording to the number of vessels to be treated. Fifty-three
ercutaneous coronary intervention centers, including all
rench university hospitals and the most active community
ospitals with a large coronary angioplasty volume (annual
ase load 600 angioplasties per year) participated in the
tudy. Consecutive eligible diabetic patients were included.
or each eligible diabetic patient included by a center
stratified to single-vessel disease [SVD] or multivessel
isease [MVD] groups), a nondiabetic patient was subse-
uently included, leading to 4 separate groups of patients.
nclusion criteria. The diabetic subgroups were defined on
he basis of known history of type 1 or type 2 diabetes
ellitus for at least 3 months, requiring medical therapy
ith either oral antidiabetic agents, insulin, or both. Inclu-
ion criteria were on-label use of SES, with the exception
hat treatment of in-stent restenosis was permitted. Exclu-
ion criteria were the off-label use of SES (acute ST-
egment elevation myocardial infarction [MI] 48 h, left
ain stenosis, bifurcation lesions, saphenous vein graft
tenosis, and total chronic occlusion) and patients in whom
omplete revascularization with SES was not feasible. Com-
lete revascularization was defined as revascularization of all
ajor coronary arteries supplying viable myocardium. Func-
ional assessment of ischemia was required for every patient
ith stable conditions.
All patients were required to sign an informed consent
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
LAST  late acute stent
thrombosis
MACE  major adverse
cardiac events
MI  myocardial infarction
MVD  multivessel disease
SAE  serious adverse
event
SAT  subacute stent
thrombosis
SES  sirolimus-eluting
stent(s)
SVD  single-vessel
disease
TLR  target lesion
revascularization
TVF  target vessel failure
TVR  target vessel
revascularizationorm. However, because the objective of the registry was to aocument the safety of SES used in everyday practice,
atients included who were subsequently found to meet
xclusion criteria were kept in the analyses. Dual antiplatelet
reatment with aspirin (75 to 160 mg/day) plus clopidogrel
75 mg/day) was required for at least 3 months; thereafter,
he continued use of dual antiplatelet therapy was left to the
iscretion of the investigator but was not specifically rec-
mmended at the time of the start of the study in 2003.
After each new inclusion, the coordination center in-
ormed the investigator of which group the next patient to
e included by the center should belong. Electronic case
eport forms were completed at the end of the first in-
ospital period, at 6, 12, and 36 months, and on knowledge
f an adverse event occurring at any time up to 36 months.
hospital outpatient consultation was strongly recom-
ended for the 12-month visit. Telephone interviews and
atient questionnaires were used when this was not possible
nd particularly for the 6-month and the 3-year follow-up
isit. All major adverse cardiac events (MACE) (defined as
ardiovascular death, occurrence of an acute MI, and/or a
roven or suspected ST) as well as death from any cause and
ew revascularizations were immediately reported by fax to
he Coordination Center. The definition of acute MI was
linically driven and confirmed by creatine kinase-MB or
roponin elevation 2 the upper limit of normal. Stent
hrombosis was initially defined as “certain” (ischemic event
ollowed by evidence of thrombus on coronary angiogra-
hy), among patients presenting cardiovascular death or
cute MI as “very probable” (sudden death with preceding
hest pain) or “probable” (sudden death without preceding
hest pain), or “improbable or excluded,” by agreement of
he 5 members of the Critical Event Committee, blinded
o diabetes status and number of vessels diseased, “acute”
48 h after stent implantation), “subacute” (48 h to 30
ays after stent implantation [SAT]), “late” (30 days
LAST]), or “very late” (6 months). Stent thrombosis
fter revascularization of the stented lesion was not cen-
ored. To facilitate comparison with other studies, the “very
robable” and “probable” ST were reclassified into “probable”
nd “possible,” in accordance with the hierarchic classification
f ST from the Academic Research Consortium (16). After
ach serious adverse event (SAE), queries were sent to the
nvestigator to obtain a detailed report for assessment by the
ritical Events Committee. For SAE in which the SES was
onsidered by the investigator to be implicated, a report was
ubmitted to the French National Health authorities. New
evascularizations were defined as revascularization of the
reated lesion (TLR), the treated vessel (TVR), or another
essel (non-TVR). On-site monitoring was performed for
very patient for the inclusion/exclusion and baseline data,
nd the complete dataset was monitored on site for 50% of
he patients (including all patients who presented an SAE).
atients’ hospital records were consulted by the monitoring
eam during the follow-up period to detect any underre-
orting of SAE. Monitoring, data management, and data
nalysis were performed by the Clinical Research Center of
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August 7, 2007:501–8 Stent Thrombosis After SES in Diabetic Patientshe University Hospital of Grenoble. The study protocol
as examined by the local Ethics Committee. The Critical
vents Committee classified all major events.
tatistical analysis. PARAMETERS STUDIED. The major
afety end point was the occurrence of any MACE. A
inimum target population of 1,600 patients was pre-
efined to detect an absolute difference 2% for the
ccurrence of MACE between diabetic and nondiabetic
atients with an alpha error of 0.05 and a beta error of 0.10
1-sided test, log rank test). The probability of MACE in
he nondiabetic group was estimated to be 4% according to
revious studies. This sample size would allow detection as
ignificant of a doubling of ST rates in diabetic or multiple-
essel disease patients. The index follow-up date (1 year
fter inclusion of the last patient) was December 1, 2005.
oth TLR and TVR rates were studied, as well as the target
essel failure (TVF) rate, defined as the composite of
ccurrence of cardiovascular death, ST, and TVR (including
LR).
Discrete data are reported as number (percentage) and
ontinuous data as mean  SD when normal distribution
as not rejected. Data comparisons were performed using
n unpaired Student t test or Mann-Whitney test, a Pearson
hi-square test, or a Fisher exact test. Kaplan-Meier survival
urves were computed for the occurrence of events. A log
ank test was used for the comparison of survival curves.
nivariate analyses were performed using unadjusted values.
ultivariate analysis using a stepwise logistic regression and
Cox regression model were performed to assess the
ndependent predictors for death or stent thrombosis. The
esults of the multivariate analysis are presented as adjusted
dds ratio (OR). The statistical analysis was performed on
PSS 13-PC software (SPSS Inc., Chicago, Illinois). All
ata were analyzed independently in the Clinical Research
enter, Grenoble.
aseline Data: Comparison Between Diabetic and Nondiabetic Pati
Table 1 Baseline Data: Comparison Between Diabetic and Non
All Patients (n  1,731)
Age (yrs) 61.9 11
Female 440 (25)
Weight (kg) 78.5 14
BMI (kg/m2) 27.5 4
Obese (BMI 30 kg/m2) 354 (20)
Hypertension 929 (54)
Q-wave MI 221 (14)
Previous PTCA 511 (29)
Previous CABG 100 (6.0)
Previous stroke 47 (2.6)
Active smokers 357 (30)
Former smokers 541 (31)
Dyslipidemia 1085 (62)
Familial history of CAD 511 (30)
Renal failure 112 (6.5)
Dialysis 21 (1.2)ll data are n (%) unless otherwise indicated. *Comparison between diabetics and nondiabetics.
BMI  body mass index; CABG  coronary artery bypass graft; CAD  coronary artery disease; MI  mesults
aseline data: comparison of diabetic and nondiabetic
atients. Between January 3, 2003, and November 30,
004, 1,731 patients were included. The mean follow-up
as 465 (range 0 to 1,062) days. Seven hundred thirty
atients (43%) were MVD (356 diabetic patients and 374
ondiabetic patients), and 1,001 patients were SVD (488
iabetic patients and 513 nondiabetic patients), with an
mbalance of 43 patients between the diabetic and nondia-
etic groups, entirely due to an excess of treatment of
n-stent restenosis in nondiabetics. Baseline data were more
evere in diabetic patients (Table 1). About half of the
atients were treated for stable coronary artery disease
47.3%) and the other half after an acute coronary syn-
rome. Seventy-one percent of the patients with stable
oronary artery disease underwent at least 1 functional stress
est (67.8% electrocardiographic stress test, 50.7% isotope
tudies, and 7.9% stress echography) before revasculariza-
ion. Before revascularization, 87% of the patients were on
spirin and 79% on clopidogrel, reaching, respectively,
00% and 99% after stent implantation. Glycoprotein IIb/
IIa inhibitors were used in only 19% of the patients, with
imilar rates in diabetic and nondiabetic patients. Three
undred twenty-seven (39%) of the diabetic patients
ere on insulin therapy and 70% on oral antidiabetic
edications.
Treatment of in-stent restenosis was performed in 273
esions and 10% of the patients. Off-label indications for
ES were performed for 471 (17%) of the lesions in 321
19%) of the patients, mostly because the intervention
nvolved bifurcation, ostial lesions, heavily calcified lesions,
r very long (30 mm) stenoses. Lesion distribution was
imilar for diabetic and nondiabetic patients: 50% of pa-
ients were treated for a left anterior descending artery
tic Patients
tics (n  844) Nondiabetics (n  887) p Value*
4.3 10 59.8 11 0.001
260 (31) 180 (20) 0.001
0.5 14 76.6 13 0.001
8.5 5 26.4 4 0.001
235 (28) 119 (14) 0.001
549 (65) 380 (43) 0.001
83 (11) 138 (17) NS
210 (25) 301 (34) 0.01
48 (5.7) 52 (6.0) NS
48 (4.4) 37 (1.1) 0.001
134 (23) 223 (37) 0.001
252 (29) 289 (32) 0.05
515 (61) 570 (64) NS
194 (23) 317 (36) 0.001
74 (8.8) 38 (4.3) 0.001
1.5 (1.8) 6 (0.7) 0.035ents
diabe
Diabe
6
8
2yocardial infarction; PTCA  percutaneous transluminal coronary angiography.
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Stent Thrombosis After SES in Diabetic Patients August 7, 2007:501–8tenosis; mean lesion length, as assessed by investigators,
as not statistically higher for the diabetic patients (14.9 
mm vs. 14.5  6 mm; p  NS), but the reference vessel
iameter was smaller (2.75 0.33 mm vs. 2.96 0.32 mm;
 0.001), the minimum luminal diameter smaller (0.74
.50 mm vs. 0.84  0.52 mm; p  0.01), and the lesion
ore often “moderately” or “severely” calcified in the dia-
etic patients. There was no difference between the 2 groups
s to the length of the stents implanted (mean lengths 18.7
7 mm vs. 18.5  5 mm; p  NS), but smaller-diameter
tents were more often used in diabetic patients. Mean
ength stented was 30.2  18.8 mm in diabetic versus 30.4
18.3 mm in nondiabetic (p  NS), and 22.8  12.0 mm
n SVD versus 40.5 20.8 mm in MVD (p 0.001). Direct
tenting was less frequently performed in diabetic than in
ondiabetic patients (41% vs. 49%; p  0.01). Failure to
chieve complete revascularization with DES was noted in
5% of the patients with MVD (average 2.3 SES per patient).
ollow-up results. The 1-year follow-up rate was 98.5%.
ean follow-up was 465 days. Among the 26 patients lost
o follow-up, 14 had left for another country, 10 had been
mpossible to trace, and 2 withdrew consent to follow-up.
atients lost to follow-up came from all 4 patient groups (5
iabetic SVD, 6 diabetic MVD, 8 nondiabetic SVD, and 7
ondiabetic MVD).
ACE. After 1 year, 97.3% of nondiabetic patients were
ree of MACE versus 94.6% of diabetic patients (p [log
ank]  0.001) and 97.2% of SVD patients were free of
ACE versus 94.4% of MVD patients (p [log rank] 
.001). The MVD diabetic patients experienced the worst
ACE-free survival curve and SVD nondiabetic patients
he best (p  0.001) (Fig. 1, Table 2).
Fifty-five patients died during follow-up, and the 1-year
lobal mortality rate was 3.2% (4.9% [interquartile range
.6% to 6.6%] in diabetic patients vs. 1.6% [1.0% to 2.7%]
n nondiabetic patients), that is, 3.1 times higher in diabetic
atients than in nondiabetic patients (p [log rank]  0.001)
Fig. 2A). Cardiac death occurred in 35 patients (2.1%), was
ignificantly more frequent in diabetic patients (p [log rank]
.002), and was due to ST in 21 patients (7 confirmed, 14
robable).
tent thrombosis. Stent thrombosis occurred during
ollow-up in 45 patients (2.6%), and the ST rate at 1 year
as 2.4%. Thirty cases were confirmed as definite by
oronary angiography or autopsy (2 cases), 8 cases corre-
ponded to “probable” and 7 cases to “possible” ST, leading
o sudden death in 14 instances and occurrence of an acute
nterior ST-segment elevation MI 2 days after revascular-
zation of the left anterior descending coronary artery
ithout further angiographic confirmation in 1 case. Time
or occurrence was not different between definite and
probable or possible” ST (median 11 days [interquartile
ange 4 to 168 days] vs. 46 [6 to 187] days). The ST rates
ere significantly higher in diabetic patients than in non-
iabetic patients (p [log rank]  0.03) (Fig. 2B), and in
VD than in SVD patients (p [log rank]  0.005). pAt 1 year the ST rate was 3.2% (interquartile range 2.2%
o 4.6%) in diabetic patients versus 1.7% (interquartile range
.0% to 2.8%) in nondiabetic patients (p [log rank]  0.03)
nd 3.7% (interquartile range 2.5% to 5.3%) in MVD
atients versus 1.5% (interquartile range 0.9% to 2.5%) in
VD patients (p  0.001). The 1-year ST rate was 0.8%
4 patients) in nondiabetic SVD patients, 2.3% (11 patients)
n diabetic SVD patients, 3.0% (11 patients) in nondiabetic
VD patients, and 4.3% (15 patients) in diabetic MVD
atients (p  0.008 for the global comparison).
Twenty-three cases were acute or subacute (16 cases
1.9%] in diabetic patients and 7 cases [0.8%] in nondiabetic
atients; p 0.04), and 22 occurred after 30 days, including
1 cases occurring between 3 and 6 months after implan-
ation, 5 cases occurring between 6 months and 1 year, and
cases occurring over 1 year after implantation. The
nivariate and independent ST predictors at baseline for the
verall population, as well as for the prespecified diabetic
nd nondiabetic groups, are described in Table 3. Of note,
iabetes was no longer an ST predictor in the overall
opulation, whereas insulin-requiring diabetes remained an
ndependent predictor, both for the overall population as
ell as for the subgroup of diabetic patients. Procedural
ifficulties were mostly dissection distal to the initial SES im-
lantation site leading to 4 acute ST, 2 SAT, and 1 LAST.
During follow-up, 11 cases of ST were related to major
Figure 1 MACE-Free Survival
Major adverse cardiac event (MACE)-free survival rates in the 4 prespecified
groups of patients according to the presence of diabetes and the number of
diseased vessels. The multivessel disease (MVD) diabetic patients experi-
enced a more severe MACE-free survival curve than the other groups, and
single-vessel disease (SVD) nondiabetic patients survived better, whereas SVD
diabetic patients and MVD nondiabetic patients experienced similar survival
curves. The MACE rate was defined as a composite of occurrence of cardiovas-
cular death, acute myocardial infarction, and stent thrombosis (by any Aca-
demic Research Consortium definition).roblems with the management of the antithrombotic
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August 7, 2007:501–8 Stent Thrombosis After SES in Diabetic Patientsreatment: 2 SAT and 6 LAST occurred 2 to 10 days after
omplete withdrawal of the dual antiplatelet therapy (6 of
hem before noncardiac surgery or after a gastrointestinal
emorrhage). Two SAT were related to a delay in admin-
stration of clopidogrel after angioplasty (1 of these patients
as previously treated with oral anticoagulant therapy). In 2
ases, aspirin or clopidogrel resistance was documented after
T. Of note, as seen in the surge of the actuarial curve
Fig. 3), several cases of LAST occurred between 8 days and
ajor Cardiac Events According to Diabetic Status and Extent of C
Table 2 Major Cardiac Events According to Diabetic Status an
Diabetics
SVD
Cardiovascular death, stent thrombosis, 5.4% [4–7.1]
acute myocardial infarction 4.1% [2.7–6.3] 7.1
Stent thrombosis 3.2% [2.2–4.6]
2.3% [1.3–4.1] 4.3
Death (all causes) 4.9% [3.6–6.6]
4.3% [2.8–6.5] 5.7
racketed values are 95% confidence intervals. The p value is log rank.
MVD  multivessel coronary artery disease; SVD  single-vessel coronary artery disease.
Figure 2 Event-Free Survival in Diabetic and Nondiabetic Patien
Comparison of the event-free survival curves between diabetic and nondiabetic pa
tion (TLR); (D) target vessel failure (TVF). A TVF was defined as a composite of oc
vival curves were more severe in diabetic patients.months after discontinuation of the dual antiplatelet
herapy followed by continued prescription of single anti-
latelet therapy. This interruption was noted or highly
uspected for 12 of 20 LAST occurring after 3 months. For
he whole population, 39% of patients were still under dual
ntiplatelet therapy at last follow-up.
LR, TVR, and TVF. Target lesion revascularization,
VR, and TVF occurred in, respectively, 67 patients (78
rocedures), 125 patients (142 procedures), and 165 pa-
ary Artery Disease (1-Year Follow-Up)
ent of Coronary Artery Disease (1-Year Follow-Up)
Nondiabetics
p ValueD SVD MVD
2.7% [1.8–4] 0.001
–10.3] 1.6% [0.8–3.1] 4.3% [2.7–6.9]
1.7% [1–2.8] 0.03
–7] 0.8% [0.3–2] 3% [1.7–5.4]
1.6% [1.0–2.7] 0.001
–8.6] 0.6% [0.2–1.7] 3% [1.7–5.3]
(A) Global mortality; (B) stent thrombosis (ST); (C) target lesion revasculariza-
ce of cardiovascular death, ST, and target vessel revascularization. These sur-oron
d Ext
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% [4.8
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Stent Thrombosis After SES in Diabetic Patients August 7, 2007:501–8ients. The 1-year TLR, TVR, and TVF rates were signif-
cantly higher in diabetic patients than in nondiabetic
atients: respectively, 5.8% (interquartile range 4.4% to
.7%) versus 3.3% (interquartile range 2.3% to 4.7%), 10.5%
interquartile range 8.6% to 12.8%) versus 6.1% (interquar-
ile range 4.7% to 7.9%), and 11.8% (interquartile range
isk Factors for Stent Thrombosis
Table 3 Risk Factors for Stent Thrombosis
Univariate Analysis
Parameter Percentage p Value
Overall population
Low EF — 0.001
Previous stroke 8.5% vs. 2.5% 0.032
Diabetes 3.5% vs. 1.8% 0.033
Insulin-requiring diabetes 6.5% vs. 1.7% 0.001
Renal failure 9.8% vs. 2.1% 0.001
MVD 3.9% vs. 1.7% 0.005
Off-label stenting 4.7% vs. 2.1% 0.01
Calcified lesions 4.7% vs. 1.3% 0.001
Length stented — 0.005
Procedural difficulties — 0.001
Diabetic patients
Low EF — 0.01
Previous stroke 10.8% vs. 3.1% 0.035
Insulin-requiring diabetes 5.8% vs. 1.5% 0.001
Renal failure 10.8% vs. 2.8% 0.002
MVD 4.8% vs. 2.5% 0.006
Off-label stenting 5.4% vs. 3.1% 0.01
Calcified lesions 5.9% vs. 1.5% 0.001
Length stented — 0.031
Nondiabetic patients
Low EF — 0.06
Renal failure 7.9% vs. 1.6% 0.029
MVD 3.0% vs. 1.0% 0.029
Off-label stenting 4.1% vs. 1.4% 0.037
Calcified lesions 3.2% vs. 2.1% 0.021
Length stented — 0.08
Independent Predictors
Parameter OR [95% CI] p Value
Overall population
Previous stroke 3.2 [0.99–10] 0.052
Renal failure 3.6 [1.6–7.7] 0.001
Insulin-requiring diabetes 2.7 [1.4–5.2] 0.004
Calcified lesion 3.7 [1.8–7.7] 0.001
Lower EF (per U) 0.95 [0.93–0.97] 0.001
Length stented (per mm) 1.01 [1.0–1.03] 0.045
Diabetic patients
Previous stroke 3.9 [1.1–13] 0.03
Renal failure 2.6 [1.1–6.5] 0.046
Insulin-requiring diabetes 3.0 [1.9–4.5] 0.016
Calcified lesion 4.9 [1.8–13] 0.002
Low EF (per U) 0.98 [0.92–0.95] 0.012
Nondiabetic patients
Calcified lesion 3.0 [0.98–9.1] 0.054
Low EF (per U) 0.95 [0.91–0.99] 0.018
I confidence interval; EF ejection fraction; MVDmultivessel coronary artery disease; OR
dds ratio..8% to 13.9%) versus 6% (interquartile range 4.6% to.8%). Figures 2C and 2D show, respectively, the TLR-free
p [log rank] 0.032) and TVF-free (p [log rank] 0.001)
urvival curves. The univariate predictors of TLR were
resence of diabetes (p  0.038), particularly diabetes with
nsulin therapy (p  0.001), MVD lesions (p  0.026), and
tent length (p  0.01). The independent predictors of
LR were diabetes with insulin therapy (OR 2.1 [95%
onfidence interval (CI) 1.1 to 4] and stent length (OR 1.02
95% CI 1.01 to 1.03] per mm). The univariate predictors of
VR were presence of diabetes (p  0.007), particularly
iabetes with insulin therapy (p  0.0001), lower ejection
raction (p 0.001), MVD lesions (p 0.003), presence of
alcified lesions (p  0.001), and length stented (p 
.001). The independent predictors of TVR were diabetes
ith insulin therapy (OR 1.5 [95% CI 0.95 to 2.5]), MVD
esions (OR 1.8 [95% CI 1.1 to 32]), and length stented
OR 1.02 [95% CI 1.01 to 1.03] per mm).
omparison of diabetic patients with or without insulin
herapy. There was no difference for age, body mass index,
resence of other risk factors, or previous history of coronary
rtery disease between diabetic patients with or without
nsulin therapy. However, insulin-requiring diabetic pa-
ients were more often female (p  0.001), with a history of
enal failure (p  0.001), or on dialysis (p  0.005). Figure
shows that diabetics on insulin therapy had higher event
ates either for safety parameters (death or ST) or efficacy
arameters (TLR, TVR, or non-TVR).
iscussion
elative role of the presence of diabetes and other risk
actors for the occurrence of ST. Whereas the clinical
fficacy of SES in reducing the need for new revasculariza-
Figure 3 Occurrence of Stent Thrombosis
Cumulative curve of occurrence of subacute (SAT) or late acute (LAST) stent
thrombosis (ST) (by any Academic Research Consortium definition). Of note is
the surge of the actuarial curve between day 90 and day 180, when the dual
antiplatelet therapy was shifted to a single antithrombotic therapy for most of
the patients. 1  SAT; 2  LAST; 3  very LAST.
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August 7, 2007:501–8 Stent Thrombosis After SES in Diabetic Patientsions (TLR, TVR) is confirmed by the low rates observed in
he present population (although these rates were higher in
iabetic than in nondiabetic patients, as already reported by
thers [17]), our results show higher ST rates in diabetic
han in nondiabetic patients in univariate analysis. In earlier
tudies, the number of diabetic patients was relatively small,
etween 16% and 25% of the population included, whereas,
n accordance with the design of our prospective registry,
alf our patients were diabetic. Of note, 1-year mortality
nd ST rates were low in nondiabetic SVD patients (0.6%
nd 0.8%, respectively), and similar to those observed in
andomized trials. In contrast, diabetic patients, particularly
VD diabetic patients, had much higher mortality and ST
ates (5.7% and 4.3%, respectively). In the Stankovic registry
he 9-month ST rate was 2.1% in 147 diabetic patients
reated with SES in more than 1 artery (18), but the
efinition of ST was not specified.
It must be pointed out, however, that in multivariate
nalysis diabetes was no longer an ST predictor. The
ndependent ST predictors found were: presence of renal
ailure (and above all patients on dialysis), low ejection
raction, and “off-label” lesions treated, such as bifurcation
r very long or calcified lesions, these predictors being
lready reported by other investigators (9,14,18,19). Fur-
hermore, we found a correlation between previous history
f stroke and ST. As seen in Table 1, these clinical and
orphologic predictors of ST were more often present in
iabetic than in nondiabetic patients; diabetes is a signifi-
ant contributor to these predictors of ST. Of note, diabetic
atients on insulin therapy were particularly at risk for ST,
Figure 4 Event Rate in Diabetics
With or Without Insulin Therapy
Comparison of event rates between insulin-requiring diabetic patients (327
patients, 39%) and noninsulin treated diabetic patients (517 patients, 61%):
mortality, ST, TLR, target vessel revascularization (TVR), and non-TVR rates
were significantly higher in insulin-treated diabetic patients. DM  diabetes
mellitus; other abbreviations as in Figure 2.nd this variable remained an independent predictor of ST. sThe 1-year ST rate was 2.4%, and ST occurred in 2.6%
f the present patients during the whole duration of follow-
p. In 30 cases (1.7%), it was definite ST confirmed by
oronary angiography or autopsy, and 15 cases were adju-
icated by the critical event committee as “very probable or
robable ST.” Definition of ST varies from one study to
nother. In some earlier analyses the definition of ST seems
o be too restrictive or too broad (5,9). Restricting the
efinition of ST to those cases where angiography is
erformed gives an over-optimistic view of this major
linical problem (5). In others analyses, all deaths (sudden or
 consequence of heart failure) and every new case of acute
yocardial infarction were assigned as possible ST, which
eads to an exceedingly extended definition (9). We have
edefined our 15 patients without definite evidence of ST
ccording to the classification of the Academic Research
onsortium as “probable” or “possible” ST. After analysis of
ll available data by the Critical Event Committee, these
atients, including the 7 “possible” ST, had recent clinical
istories that were strongly suggestive of acute thrombosis;
n addition, their baseline characteristics (mean age, patient
roup, or timing of occurrence of the ST) were not different
rom those of the patients with “definite” ST.
ole of the antithrombotic regimen. The antithrombotic
egimen seems to have a definite influence on the clinical
utcomes: Withdrawal of dual antiplatelet therapy has been
eported as a cause of ST both early (8) and late (6,7,9) after
ES implantation. This mechanism was documented for 8
2 SAT, 6 LAST) of the present patients (6 before noncar-
iac surgery or after gastrointestinal hemorrhage), leading to
he death of the patients. Figure 3 shows a clear surge in the
vent curve for ST between 3 and 6 months, i.e., in the
eeks that followed the cessation of combination antiplate-
et therapy required by the present protocol. Only 39% of
he present patients were still under dual antiplatelet therapy
t last follow-up. This constitutes a strong plea for pro-
onged dual antiplatelet therapy after DES implantation.
tudy limitations. Because the index follow-up date were
year after the inclusion of the last patient, this analysis can
ot assess the percentage of very late ST beyond 1 year. The
ngoing 3-year follow-up will address this question. The
resent study does not attempt a comparison of the safety
rofile of BMS compared with DES. In the PRESTO
Prevention of Restenosis With Tranilast and Its Out-
omes) trial, the BMS occlusion rate was 3.2% in nondia-
etic and 3.7% in diabetic patients in the subgroup analysis
f 2,000 patients with angiographic control. For the whole
opulation included in the PRESTO trial, the MACE rate
as significantly higher in diabetic patients than for the
ondiabetic patients (20). In the recently published
ASKET-LATE (Late Clinical Events Related to Late
tent Thrombosis After Stopping Clopidogrel) observa-
ional study, the rate of cardiac death/MI, possibly related to
T, 12 months after discontinuation of clopidogrel, was
ignificantly higher after implantation of a DES than with a
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larger series (16).
onclusions
n the light of our findings, it seems that some cases of ST
ould be avoided by a better implementation of the anti-
latelet regimen. Better information to the patient and to all
hysicians involved in his/her care management can prevent
atastrophic cases related to complete withdrawal of dual
ntiplatelet therapy, particularly when noncardiac surgery is
lanned (e.g., in France, an information card is now given to
he patient). In the present study, some cases of LAST
after 3 months) were observed when the dual antithrom-
otic therapy was changed to aspirin alone. If this registry
rovides some proof of the necessity for prolonged dual
ntiplatelet therapy in these patients, further analyses are
eeded to assess the optimal duration of dual antiplatelet
herapy after implantation of a DES, particularly in the
iabetic population. The present findings suggest that
iabetic multiple-vessel disease patients have a poorer out-
ome after SES implantation, but only a randomized
omparison with surgery will help physicians to choose the
est therapeutic option for their patients.
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